|
Seeing Alzheimer's amyloids
May 13, 2008In an important step toward demystifying the role protein clumps play in the development of neurodegenerative disease, researchers have created a stunning three-dimensional picture of an Alzheimer's peptide aggregate using electron microscopy. The study, in this week's issue of the Proceedings of the National Academy of Sciences, reports that researchers from Brandeis University in Waltham, Mass., and the Leibniz Institut in Jena, Germany, have shown-for the first time-how A-beta peptide, found in the brains of Alzheimer's patients, forms a spaghetti-like protein mass called an amyloid fibril.
"This study is a significant advance regarding our understanding of how these fibrils are built from the A-beta peptide (Alzheimer's peptide)," said co-author Nikolaus Grigorieff, a biophysicist at Brandeis University and an investigator with the Howard Hughes Medical Institute. "People have been guessing for decades what these fibrils look like, but now we have an actual 3D image."
In healthy people A-beta peptide does not aggregate, but in Alzheimer's patients it clumps first and then forms long fibrils, like tentacles, in a so-called cross-beta structure. Scientists disagree whether it is the clumps that kill neurons in the brain or the fibrils. Grigorieff wants to discover which part of the amyloid structure is toxic; that would be an important step in designing drugs to prevent or treat disease.
Amyloid structure-the particular way a protein or peptide clumps together-is linked to other neurodegenerative conditions as well, including Parkinson's and Creutzfeldt-Jakob disease. "The amyloid way of folding and aggregation seems to be a fundamental property of proteins and peptides" explained Grigorieff. "We know how most normal proteins fold, but what drives amyloid formation?"
It's a question that has dogged structural biologists and biochemists for a long time but stubbornly refuses elucidation. Researchers using x-ray crystallography have so far been unable to obtain crystals from fibrils of full-length polypeptide chains. Structural models based on NMR data have also come up short. Scientists have made do with studying fragments of the A-beta peptide. The major barrier to determining the structure of A-beta fibrils is that the same peptide will exasperatingly assemble differently from fibril to fibril-unlike normal proteins, which reliably fold up the same way every time.
Grigorieff and his colleagues overcame this barrier by generating fibrils in a test tube under conditions that reduce the variability between fibrils, and by selecting about 200 images of fibrils that were most similar to each other and averaging them on a computer.
An expert at high resolution electron cryo-microscopy of protein complexes and macromolecular machines, Grigorieff said his lab made an image of the A-beta fibril at a resolution of eight Angstroms, revealing useful detail at a magnification of roughly a million times. Short of atomic resolution by a factor of 2.5 to 3, the image revealed how the peptide, a series of linked amino acids, was arranged in the tape-like fibril.
"The next step will be a 3-D image that tells us exactly where all the amino acids are," postulates Grigorieff. "This will tell us more about the chemical and biological properties of A-beta fibrils that we need to know to understand their role in Alzheimer's."
Brandeis University
Amyloid structure-the particular way a protein or peptide clumps together-is linked to other neurodegenerative conditions as well, including Parkinson's and Creutzfeldt-Jakob disease. "The amyloid way of folding and aggregation seems to be a fundamental property of proteins and peptides" explained Grigorieff. "We know how most normal proteins fold, but what drives amyloid formation?"
It's a question that has dogged structural biologists and biochemists for a long time but stubbornly refuses elucidation. Researchers using x-ray crystallography have so far been unable to obtain crystals from fibrils of full-length polypeptide chains. Structural models based on NMR data have also come up short. Scientists have made do with studying fragments of the A-beta peptide. The major barrier to determining the structure of A-beta fibrils is that the same peptide will exasperatingly assemble differently from fibril to fibril-unlike normal proteins, which reliably fold up the same way every time.
Grigorieff and his colleagues overcame this barrier by generating fibrils in a test tube under conditions that reduce the variability between fibrils, and by selecting about 200 images of fibrils that were most similar to each other and averaging them on a computer.
An expert at high resolution electron cryo-microscopy of protein complexes and macromolecular machines, Grigorieff said his lab made an image of the A-beta fibril at a resolution of eight Angstroms, revealing useful detail at a magnification of roughly a million times. Short of atomic resolution by a factor of 2.5 to 3, the image revealed how the peptide, a series of linked amino acids, was arranged in the tape-like fibril.
"The next step will be a 3-D image that tells us exactly where all the amino acids are," postulates Grigorieff. "This will tell us more about the chemical and biological properties of A-beta fibrils that we need to know to understand their role in Alzheimer's."
Brandeis University
Amyloid News and Current Amyloid Events RSSCalcium may be the key to understanding Alzheimer's disease
Researchers at the University of Pennsylvania School of Medicine have shown that mutations in two proteins associated with familial Alzheimer's disease disrupt the flow of calcium ions within neurons. The two proteins, called PS1 and PS2 (presenilin 1 and 2), interact with a calcium release channel in an intracellular cell compartment.
Scientists demonstrate means of reducing Alzheimer's-like plaques in fly brain
Neuroscientists at Cold Spring Harbor Laboratory (CSHL) are part of a collaboration that has succeeded in demonstrating that overexpression of an enzyme in the brain can reduce telltale deposits causally linked with Alzheimer's disease.
Ionophore reverses Alzheimer's within days in mouse models
Scientists report a remarkable improvement in Alzheimer's transgenic mice following treatment with a new drug. The study, published by Cell Press in the July 10th issue of the journal Neuron, provides the first demonstration that an ionophore, a compound that transports metal ions across cell membranes, can elicit rapid and pronounced improvement in neuropathology and cognitive function in mouse models of Alzheimer's Disease (AD).
Can tomatoes carry the cure for Alzheimer's?
The humble tomato could be a suitable carrier for an oral vaccine against Alzheimer's disease, according to HyunSoon Kim from the Korea Research Institute of Bioscience and Biotechnology (KRIBB) in Korea and colleagues from Digital Biotech Inc. and the Department of Biological Science at Wonkwang University. Although their research1, just published online in Springer's journal Biotechnology Letters, is still in the early stages, it is a promising first step towards finding an edible vaccine against the neurodegenerative disease.
The good and the bad of a potential Alzheimer's target
Research in fruit flies has shown that enhancing the production of a protein called neprilysin can reduce the formation of plaques and neuron death associated with Alzheimer's, at the expense of reducing the flies' lifespan.
Anti-inflammatory drug blocks brain plaques
Brain destruction in Alzheimer's disease is caused by the build-up of a protein called amyloid beta in the brain, which triggers damaging inflammation and the destruction of nerve cells.
Scientists use Iceland's genealogical database to pinpoint the heritage of a deadly disease
A collaboration of scientists from Iceland and the United States has used Iceland's genealogical database* to trace the ancestors of patients suffering from hereditary cystatin C amyloid angiopathy (HCCAA). Analysis shows that the deadly mutation in the cystatin C gene, L68Q, derives from a common ancestor born roughly 18 generations ago, around 1550AD. Details are published June 20th in the open-access journal PLoS Genetics.
Study indicates grape seed extract may reduce cognitive decline associated with Alzheimer's disease
A compound found in grape seed extract reduces plaque formation and resulting cognitive impairment in an animal model of Alzheimer's disease, new research shows. The study appears in the June 18 issue of The Journal of Neuroscience.
Advance towards early Alzheimer's diagnosis
An Australian research project has found a way to bring forward the detection of early stage Alzheimer's disease by up to 18 months.
Molecular imaging sheds new light on progression of Alzheimer's disease
In the past, physicians were able only to follow the progression of Alzheimer's disease (AD) through careful clinical histories, noting the often subtle changes associated with cognitive decline over a number of years.
More Amyloid News Articles
| © 2008 BrightSurf.com |